<DOC>
	<DOCNO>NCT00216164</DOCNO>
	<brief_summary>Rituximab demonstrate sensitize drug-resistant NHL cell cytotoxic action several chemotherapy agent enhance sensitivity tumor cell chemotherapy-induced apoptosis . Gemcitabine , nucleoside analog use several malignancy , show promising activity patient refractory Hodgkin 's disease low-grade NHL . The combination rituximab gemcitabine may synergistic cytotoxic action patient relapse refractory DLBCL possibly lead improved response rate demonstrable clinical benefit . This trial investigate efficacy combination rituximab gemcitabine treat patient relapsed refractory DLBCL .</brief_summary>
	<brief_title>Rituximab Gemcitabine Patients With Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Rituximab 375 mg/m2 day 1 21 day cycle - Gemcitabine 1000 mg/m2 day 1 8 21 day cycle Subgroup 1 . Relapsed respond first line chemotherapy , candidate salvage high-dose chemotherapy . Subgroup 2 . Failure achieve complete response relapse respond salvage chemotherapy ( number salvage regimens allow ) , candidate high-dose chemotherapy . Subgroup 3 . Refractory first line chemotherapy and/or 1 ( one ) salvage chemotherapy regimen . Subgroup 4 . Progression high-dose chemotherapy . Patients progressive disease within 3 month high-dose chemotherapy allow . Performance Status : ECOG performance status 0 , 1 , 2 Life expectancy : Not specify Hematopoietic : · - ANC ≥ 1,000/mm3· - Platelets ≥ 100,000/mm3 Hepatic : · - Total bilirubin ≤ 2.0 x ULN· - ALT AST ≤ 3 x ULN unless lymphoma involves liver CT scan AST ALT &lt; 5 x ULN Renal : · - Serum creatinine ≤ 2.0 mg/dl ( except patient dialysis ) Cardiovascular : · - Not specify Pulmonary : · - Not specify</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Biopsyproven DLBCL meet criterion 4 subgroup Transformed DLBCL previous indolent NHL meet criterion 4 subgroup receive least one standard chemotherapy regimen aggressive NHL biopsy upon progression disease obtain confirm presence DLBCL . The concomitant presence component low grade lymphoma NOT exclude participation Measurable disease per Standardized Response Criteria NonHodgkin 's Lymphoma Prior gemcitabine therapy allow . Negative pregnancy test No history lifethreatening reaction rituximab . No history gemcitabine intolerance ; prior gemcitabine therapy allow . No history malignancy last 5 year ( basal cell carcinoma skin exclude ) . No central nervous system cerebrospinal fluid involvement No investigational drug receive within 30 day prior register protocol therapy . No active infection . No current breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Lymphoma</keyword>
</DOC>